{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:31Z","timestamp":1787019571878,"version":"build-2736575974"},"reference-count":69,"publisher":"American Society of Hematology","issue":"7","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Therapeutic vaccination has long been a promising avenue for cancer immunotherapy but is often limited by tumor heterogeneity. The genetic and molecular diversity between patients often results in variation in the antigens present on cancer cell surfaces. As a result, recent research has focused on personalized cancer vaccines. Although promising, this strategy suffers from time-consuming production, high cost, inaccessibility, and targeting of a limited number of tumor antigens. Instead, we explore an antigen-agnostic polymeric in situ cancer vaccination platform for treating blood malignancies, in our model here with acute myeloid leukemia (AML). Rather than immunizing against specific antigens or targeting adjuvant to specific cell-surface markers, this platform leverages a characteristic metabolic and enzymatic dysregulation in cancer cells that produces an excess of free cysteine thiols on their surfaces. These thiols increase in abundance after treatment with cytotoxic agents such as cytarabine, the current standard of care in AML. The resulting free thiols can undergo efficient disulfide exchange with pyridyl disulfide (PDS) moieties on our construct and allow for in situ covalent attachment to cancer cell surfaces and debris. PDS-functionalized monomers are incorporated into a statistical copolymer with pendant mannose groups and TLR7 agonists to target covalently linked antigen and adjuvant to antigen-presenting cells in the liver and spleen after IV administration. There, the compound initiates an anticancer immune response, including T-cell activation and antibody generation, ultimately prolonging survival in cancer-bearing mice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012529","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T15:04:35Z","timestamp":1707318275000},"page":"1747-1759","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9984-3638","authenticated-orcid":false,"given":"Anna J.","family":"Slezak","sequence":"first","affiliation":[{"name":"1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-8950","authenticated-orcid":false,"given":"Kevin","family":"Chang","sequence":"additional","affiliation":[{"name":"1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-3856","authenticated-orcid":false,"given":"Taryn N.","family":"Beckman","sequence":"additional","affiliation":[{"name":"2Committee on Molecular Metabolism and Nutrition, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0585-5827","authenticated-orcid":false,"given":"Kirsten C.","family":"Refvik","sequence":"additional","affiliation":[{"name":"1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4669-4813","authenticated-orcid":false,"given":"Aaron T.","family":"Alpar","sequence":"additional","affiliation":[{"name":"1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail L.","family":"Lauterbach","sequence":"additional","affiliation":[{"name":"1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-7852","authenticated-orcid":false,"given":"Ani","family":"Solanki","sequence":"additional","affiliation":[{"name":"3Animal Resource Center, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1793-2732","authenticated-orcid":false,"given":"Jung Woo","family":"Kwon","sequence":"additional","affiliation":[{"name":"4Department of Pathology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Gomes","sequence":"additional","affiliation":[{"name":"1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6574-9053","authenticated-orcid":false,"given":"Aslan","family":"Mansurov","sequence":"additional","affiliation":[{"name":"1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Hubbell","sequence":"additional","affiliation":[{"name":"1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL"},{"name":"5Committee on Immunology, University of Chicago, Chicago, IL"},{"name":"6Committee on Cancer Biology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"2024040514363741300_bib1","author":"Vakiti","year":"2018"},{"issue":"4","key":"2024040514363741300_bib2","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.beha.2019.101094","article-title":"Will new agents impact survival in AML?","volume":"32","author":"Rowe","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"2024040514363741300_bib3","first-page":"375","article-title":"Advances in acute myeloid leukemia","author":"Newell","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2024040514363741300_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/BS9.0000000000000140","article-title":"Immune therapy: a new therapy for acute myeloid leukemia","volume":"5","author":"Tian","year":"2023","journal-title":"Blood Sci"},{"key":"2024040514363741300_bib5","doi-asserted-by":"crossref","first-page":"656218","DOI":"10.3389\/fonc.2021.656218","article-title":"Immunotherapy in acute myeloid leukemia: where we stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front Oncol"},{"issue":"22","key":"2024040514363741300_bib6","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2024040514363741300_bib7","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"issue":"9","key":"2024040514363741300_bib8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"2024040514363741300_bib9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"2024040514363741300_bib10","doi-asserted-by":"crossref","first-page":"106420","DOI":"10.1016\/j.leukres.2020.106420","article-title":"Analysis of estimated clinical benefit of newly approved drugs for us patients with acute myeloid leukemia","volume":"96","author":"Tran","year":"2020","journal-title":"Leuk Res"},{"issue":"13","key":"2024040514363741300_bib11","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (ft-2102) induces durable complete remissions in patients with relapsed or refractory idh1-mutated aml","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"26","key":"2024040514363741300_bib12","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.18632\/oncotarget.26811","article-title":"Evaluation of gilteritinib in combination with chemotherapy in preclinical models of flt3-itd+ acute myeloid leukemia","volume":"10","author":"Ueno","year":"2019","journal-title":"Oncotarget"},{"key":"2024040514363741300_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.exphem.2022.03.008","article-title":"Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without dnmt3a mutations","volume":"110","author":"Shabashvili","year":"2022","journal-title":"Exp Hematol"},{"issue":"6","key":"2024040514363741300_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","article-title":"Tlr agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J\u00a0Leukoc Biol"},{"key":"2024040514363741300_bib15","doi-asserted-by":"crossref","first-page":"939249","DOI":"10.3389\/fonc.2022.939249","article-title":"Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"2024040514363741300_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.biomaterials.2013.10.003","article-title":"Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response","volume":"35","author":"Thomas","year":"2014","journal-title":"Biomaterials"},{"issue":"6","key":"2024040514363741300_bib17","doi-asserted-by":"crossref","first-page":"e20952","DOI":"10.1371\/journal.pone.0020952","article-title":"Poly (i: C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by dc","volume":"6","author":"Lion","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"2024040514363741300_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s40425-019-0625-x","article-title":"A\u00a0multipeptide vaccine plus toll-like receptor agonists LPS or polyiclc in combination with incomplete freund\u2019s adjuvant in melanoma patients","volume":"7","author":"Melssen","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"2024040514363741300_bib19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/leu.2014.293","article-title":"The role of TLR8 signaling in acute myeloid leukemia differentiation","volume":"29","author":"Ignatz-Hoover","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2024040514363741300_bib20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006","article-title":"Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells","volume":"95","author":"Decker","year":"2000","journal-title":"Blood"},{"issue":"12","key":"2024040514363741300_bib21","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s12094-022-02917-5","article-title":"Therapeutic applications of toll-like receptors (TLRs) agonists in AML","volume":"24","author":"Peng","year":"2022","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"2024040514363741300_bib22","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/acscentsci.2c00704","article-title":"Tumor cell-surface binding of immune stimulating polymeric glyco-adjuvant via cysteine-reactive pyridyl disulfide promotes antitumor immunity","volume":"8","author":"Slezak","year":"2022","journal-title":"ACS Cent Sci"},{"issue":"2","key":"2024040514363741300_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41563-018-0256-5","article-title":"Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity","volume":"18","author":"Wilson","year":"2019","journal-title":"Nat Mater"},{"key":"2024040514363741300_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.mito.2019.04.010","article-title":"Overview of thioredoxin system and targeted therapies for acute leukemia","volume":"47","author":"Xie","year":"2019","journal-title":"Mitochondrion"},{"issue":"33","key":"2024040514363741300_bib25","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1038\/s41388-021-01924-0","article-title":"Thioredoxin reductase is a major regulator of metabolism in leukemia cells","volume":"40","author":"Karunanithi","year":"2021","journal-title":"Oncogene"},{"key":"2024040514363741300_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2016.00041","article-title":"Hypoxia and hypoxia-inducible factors in leukemias","volume":"6","author":"Deynoux","year":"2016","journal-title":"Front Oncol"},{"key":"2024040514363741300_bib27","doi-asserted-by":"crossref","first-page":"973978","DOI":"10.3389\/fonc.2022.973978","article-title":"Hypoxic stress and hypoxia-inducible factors in leukemias","volume":"12","author":"Magliulo","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"2024040514363741300_bib28","first-page":"235","article-title":"The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1\u03b1 and vascular endothelial growth factor formation","volume":"2","author":"Welsh","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2024040514363741300_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12185-012-1070-5","article-title":"Effects of hypoxia and HIFs on cancer metabolism","volume":"95","author":"Mucaj","year":"2012","journal-title":"Int J Hematol"},{"issue":"24","key":"2024040514363741300_bib30","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1158\/1078-0432.CCR-12-1149","article-title":"Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer","volume":"18","author":"Adams","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"2024040514363741300_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"2024040514363741300_bib32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3892\/ijo.2015.3069","article-title":"TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer","volume":"47","author":"Grimmig","year":"2015","journal-title":"Int J Oncol"},{"issue":"2","key":"2024040514363741300_bib33","first-page":"144","article-title":"Dual character of toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions","volume":"1835","author":"Yu","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2024040514363741300_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88\u2013dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"issue":"116","key":"2024040514363741300_bib35","first-page":"e54270","article-title":"A\u00a0detailed protocol for characterizing the murine C1498 cell line and its associated leukemia mouse model","author":"Mopin","year":"2016","journal-title":"JoVE"},{"issue":"2","key":"2024040514363741300_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2024040514363741300_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101345","article-title":"Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics","volume":"5","author":"Wallace","year":"2024","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"2024040514363741300_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12865-016-0186-4","article-title":"Antigen presenting capacity of murine splenic myeloid cells","volume":"18","author":"Hey","year":"2017","journal-title":"BMC Immunol"},{"key":"2024040514363741300_bib39","author":"Kaufman","year":"2018"},{"key":"2024040514363741300_bib40","volume-title":"C1498: a murine model for acute myelogenous leukemia (AML)","author":"Daniel","year":"2017"},{"issue":"6","key":"2024040514363741300_bib41","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.3892\/or.2015.4297","article-title":"A\u00a0CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment","volume":"34","author":"Han","year":"2015","journal-title":"Oncol Rep"},{"key":"2024040514363741300_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/978-3-030-34461-0_53","article-title":"Effective murine model induction for niche study in immune cells against leukemia","volume":"1232","author":"Kim","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"2024040514363741300_bib43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/leu.2017.307","article-title":"A\u00a0vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target","volume":"32","author":"Yan","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2024040514363741300_bib44","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1038\/bcj.2017.52","article-title":"CD123 target validation and preclinical evaluation of adcc activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","volume":"7","author":"Xie","year":"2017","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024040514363741300_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.161.1.1","article-title":"Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies","volume":"161","author":"Kipps","year":"1985","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"2024040514363741300_bib46","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur J Immunol"},{"issue":"12","key":"2024040514363741300_bib47","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.4049\/jimmunol.1801184","article-title":"CD8\u03b1+ dendritic cells dictate leukemia-specific CD8+ T cell fates","volume":"201","author":"Kline","year":"2018","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"2024040514363741300_bib48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41375-021-01432-w","article-title":"Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy","volume":"36","author":"Johnson","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2024040514363741300_bib49","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ijc.11574","article-title":"CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival","volume":"108","author":"Palma","year":"2004","journal-title":"Int J Cancer"},{"issue":"1","key":"2024040514363741300_bib50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40880-019-0419-z","article-title":"CD137 expression in cancer cells: regulation and significance","volume":"39","author":"Glorieux","year":"2019","journal-title":"Cancer Commun"},{"issue":"11","key":"2024040514363741300_bib51","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/2326-6066.CIR-13-0208","article-title":"Murine splenic CD4+ T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity","volume":"2","author":"Nelles","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2024040514363741300_bib52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-017-0235-4","article-title":"Differential phenotypes of memory CD4 and CD8\u00a0T cells in the spleen and peripheral tissues following immunostimulatory therapy","volume":"5","author":"Sckisel","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"2024040514363741300_bib53","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-l1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"2024040514363741300_bib54","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3389\/fimmu.2020.01710","article-title":"PD-l1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia","volume":"11","author":"Dong","year":"2020","journal-title":"Front Immunol"},{"key":"2024040514363741300_bib55","author":"Delluc","year":"2006"},{"issue":"10","key":"2024040514363741300_bib56","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","article-title":"Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia","volume":"15","author":"Szczepanski","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2024040514363741300_bib57","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.3324\/haematol.2018.206821","article-title":"Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival","volume":"104","author":"Mondet","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2024040514363741300_bib58","doi-asserted-by":"crossref","first-page":"2249948","DOI":"10.1002\/eji.202249948","article-title":"The thioredoxin system: balancing redox responses in immune cells and tumors","volume":"53","author":"Muri","year":"2023","journal-title":"Eur J Immunol"},{"issue":"20","key":"2024040514363741300_bib59","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1158\/0008-5472.CAN-19-0515","article-title":"Targeting myeloperoxidase disrupts mitochondrial redox balance and overcomes cytarabine resistance in human acute myeloid leukemia","volume":"79","author":"Hosseini","year":"2019","journal-title":"Cancer Res"},{"issue":"11","key":"2024040514363741300_bib60","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/sj.leu.2403930","article-title":"Antigen-specific cellular immunotherapy of leukemia","volume":"19","author":"Van Driessche","year":"2005","journal-title":"Leukemia"},{"key":"2024040514363741300_bib61","doi-asserted-by":"crossref","first-page":"837457","DOI":"10.3389\/fimmu.2022.837457","article-title":"CD19-targeted immunotherapies for diffuse large B-cell lymphoma","volume":"13","author":"Gambella","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"2024040514363741300_bib62","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2404242","article-title":"Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation","volume":"20","author":"Xu","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"2024040514363741300_bib63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2024040514363741300_bib64","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.12732","article-title":"CD 137 ligand signalling induces differentiation of primary acute myeloid leukaemia cells","volume":"165","author":"Cheng","year":"2014","journal-title":"Br J Haematol"},{"issue":"9","key":"2024040514363741300_bib65","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acs.molpharmaceut.2c00392","article-title":"Design and characterization of immune-stimulating imidazo [4, 5-c] quinoline antibody-drug conjugates","volume":"19","author":"Fang","year":"2022","journal-title":"Mol Pharm"},{"issue":"1","key":"2024040514363741300_bib66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat Cancer"},{"issue":"7_Supplement","key":"2024040514363741300_bib67","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1538-7445.AM2023-1863","article-title":"Evaluation of BDB101, a first-in-class TLR7\/8 dual agonist conjugated to an anti-PD-l1 mAb, in cancer treatment","volume":"83","author":"Yang","year":"2023","journal-title":"Cancer Res"},{"issue":"12","key":"2024040514363741300_bib68","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","article-title":"Preclinical characterization and phase I study of an anti\u2013HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2024040514363741300_bib69","doi-asserted-by":"crossref","first-page":"113553","DOI":"10.1016\/j.jim.2023.113553","article-title":"Development and application of an in\u00a0vitro assay to assess target-independent B-cell activation by targeted TLR7 immune agonists","volume":"522","author":"Chen","year":"2023","journal-title":"J\u00a0Immunol Methods"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1747\/2220758\/blooda_adv-2023-012529-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1747\/2220758\/blooda_adv-2023-012529-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T10:37:10Z","timestamp":1712313430000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/7\/1747\/514844\/Cysteine-binding-adjuvant-enhances-survival-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012529","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}